Novo Nordisk
Aspect Biosystems Expands Novo Nordisk Partnership, Signaling Broader Pharma Interest
Aspect Biosystems and Novo Nordisk are expanding their partnership. The duo had previously made a deal worth up to $2.6 billion in 2023. Then the deal centered on drug discovery…
Game-Changing $115M for Aspect Biosystems’ Bioprinted Tech
Pioneering solutions for metabolic and endocrine diseases, Vancouver-based Aspect Biosystems raised $115 million in Series B funding to advance its bioprinted tissue technology. Led by investment firm Dimension, the round…
Canadian Government Invests $75M More in Aspect Biosystems
Canadian bioprinting startup Aspect Biosystems has received a $72.75 million investment from Canada and the province of British Columbia. This supports earlier investments amounting to $200 million in Aspect’s technology…
Aspect Biosystems Strikes $2.6B Bioprinted Tissue Deal with Novo Nordisk
Bioprinting collaborations are heating up in 2023. In one of the biggest moves of the bioprinting industry, Canadian startup Aspect Biosystems and Danish pharma giant Novo Nordisk (CPH: NOVO-B) struck…
